Seven drugmakers report AI gains in early drug discovery
According to the report, senior researchers from seven major pharmaceutical companies said AI has accelerated early drug development, with some time savings reported at up to half. Novo Nordisk said AI reduced iterations for designing, producing and testing new molecules from about eight to three, while Novartis said the average time from project launch to candidate selection fell from three years to about 18 months to two years. Sanofi said an AI-assisted approach allowed it to skip a dose-selection study and advance the asthma candidate lunsekimig by at least a year. These are company-reported results; the report says whether AI improves clinical-development success or approval rates remains unverified.
The disclosures show AI being used in molecule design, candidate screening and safety-risk identification rather than only administrative tasks. They also highlight the unresolved gap between faster early-development work and potential gains in clinical success, which the report says still require validation.

全球多家大型制药公司的高级科研人员表示,今年以来,人工智能(AI)显著加快了药物研发早期阶段的工作进程,将新分子研发及推进至临床试验所需的时间最多缩短了一半。葛兰素史克、百时美施贵宝、诺华、礼来、诺和诺德、阿斯利康和赛诺菲均表示,它们已不再局限于利用AI处理监管申报文件等基础工作,而是开始将这项技术应用于分子......
本文来自微信公众号: 财联社 ,作者:夏军雄
全球多家大型制药公司的高级科研人员表示,今年以来,人工智能(AI)显著加快了药物研发早期阶段的工作进程,将新分子研发及推进至临床试验所需的时间最多缩短了一半。
#GSK#Bristol Myers Squibb#Novartis#Eli Lilly#Novo Nordisk#AstraZeneca#Sanofi#Anthropic#Claude Science#TuneLab#lunsekimig